Atlas Trials

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

Clinical trial NCT03236129 · UNKNOWN

Trial details

NCT number
NCT03236129
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Hematological MalignanciesRegulatory T Cell DepletionRelapse
Start date
2018-02-22
Primary completion
2025-02-01
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.